News

News

Pharmacolog deltog på Aktiespararnas Aktiedagen

Igår, torsdag den 7 maj, deltog Pharmacologs VD Hans Dahlin och försäljningschef Karl-Erik Carlström på Aktiespararnas Aktiedag som arrangerades på Operaterrassen i Stockholm. Hans Dahlin presenterade bolaget och den pågående emissionen inför noteringen på AktieTorget som avslutas den 11 maj. Karl-Erik Carlström förevisade bolagets färdiga produkt DrugLog och redogjorde för dess marknadspotential. Efter presentationen utfrågades Hans Dahlin och Karl-Erik Carlström av Gunnar Ek från Aktiespararna. Den webb-sända presentationen och utfrågningen finns att se på Internet via länken: http://aktiespararna.media.fnf.nu/33/aktiedagen_2015_stockholm_maj/3

News

Pharmacolog deltar på Sedemera-dagen i Göteborg

Sedemera Fondkomission arrangerar under Tisdagen den 5 Maj ”Sedemera-dagen” i Göteborg. Pharmacolog deltar och presenterar företaget i samband med nyemissionen som just nu pågår. Sista teckningsdag är 11 Maj. Se hela programet för Sedemera-dagen. http://www.sedermeradagen.se/goteborg-2015/dagsschema-goteborg/ Anmälan sker på http://www.sedermeradagen.se/goteborg-2015/ Mer information om nyemissionen hittar du på vår kampanjsida. www.pharmacolog.se/nyemission2015  

News

AktieTorget har godkänt Pharmacologs aktie för notering

Publik nyemission och planerad notering på AktieTorget Teckningstiden för emissionen löper under perioden 13 april – 11 maj 2015. Erbjudandet i sammandrag Teckningstid:                     13 april – 11 maj 2015 Teckningskurs:                  12 kr per aktie Emissionsvolym:               Emissionen uppgår till 9 000 000 kronor fördelat på 750 000 aktier Minsta teckningspost:      500 aktier Marknadsnotering:           Första handelsdagen på AktieTorget beräknas till den 8 juni 2015 Välkommen till informationsträffar Under emissionsperioden genomförs följande informationsträffar där VD Hans Dahlin och ledningsgruppen presenterar bolaget, aktuella framtidsplaner och bakgrunden till emissionen. 9/4 Stockhol...

News

Gunnar Mattson new Chairman of the Board

We welcome Gunnar Mattson who has accepted the position as Chairman of the Board at Pharmacolog. Gunnar has a law degree from the University of Uppsala and has also studied law at the University of Minnesota, USA. He is a member of the Swedish Bar Association since 1994. He is a partner of Advokatfirman Lindahl, one of Sweden’s largest law firms, since 1996. His practice primarily concerns company law, venture capital as well as Swedish and international agreements. Gunnar is very active within pharmaceuticals, biotech, diagnostics and medtech. He was responsible for Lindahl’s practice within life sciences during 2009 – 2014 and is ranked as one of Sweden’s leading lawyers within the sector. He is currentl...

News

Thank you for visiting us on EAHP2015!

We want to thank all of you who visited our booth on the EAHP2015 exhibition in Hamburg. The show was a big success for us with a lot of interest for us and our product, DrugLog®. We hope that we could answer all your questions. If you have further questions please contact us and we will do our best to help you. We look forward to hear from you soon again. Best regards The Pharmacolog team

News

Pharmacolog AB Scientific Advisory Board

Pharmacolog have formed a Scientific Advisory Board that will guide the team in future product development. The Scientific Advisory Board will play a very important role in guiding the Pharmacolog team in question concerning design choices and functionality priorities when developing new products for IV drug management and new treatment methodology. All members of the advisory board have extensive experience from different areas of the medical field which will ensure a balanced and detailed input for the product development team at Pharmacolog. Bengt Dahlström Bengt Dahlström is Associate Professor in Pharmacokinetics and Drug Therapy at the University of Uppsala, Sweden and has published over 50 scientif...

News

Visit Pharmacolog AB at the EAHP 2015 exhibit in Hamburg, 25-27 March 2015

Pharmacolog will be represented at the European Association Hospital Pharmacists conference in Hamburg, Germany, 25-27 March. This will mark the official launch of the company’s first commercial product, DrugLog®. The system provides a fast and easy way for pharmacists and hospital staff to verify that the proposed treatment with intravenous drugs have the proper content and concentration, before it is injected into patients. Please visit us in the booth #22 If you like to schedule a meeting with us during the conference please feel free to contact us in advance.

News

Pharmacolog introduce its first commercial product, DrugLog.

The system provides a fast and easy way for pharmacists and hospital staff to verify that the proposed treatment with intravenous drugs have the proper content and concentration, before it is injected into patients. Numerous studies and reports in recent years have revealed a major problem with incorrect treatment with intravenous drugs. A number of serious cases, where patients are harmed and / or death, has also attracted attention in the media. DrugLog gives staff who prepares intravenous drug an opportunity to quickly check that no mistakes have been made in the calculation or management of the drug before the treatment is injected into the patient. “Studies have shown that 85% of all serious med...

News

Pharmacolog has successfully finalized a share issue targeted at the investment group of Aktietorget Väst (ATVäst) and Almi Invest

Pharmacology has successfully finalized a share issue targeted at the investment group of Aktietorget Väst (ATVäst) and Almi Invest. The new equity (4 million SEK) will make it possible to tie new personnel to the company for further development of the DrugLog technology and international marketing and sales. “I am very pleased about the huge interest shown by ATVäst’s investment group and Almi Invest, which will increase the probability for a commercial launching of DrugLog on the European market early 2015”, says Hans Dahlin, the founder and CEO of Pharmacolog.

News

EPO grant Pharmacolog´s patent application

European Patent Organisation (EPO) has decided to grant Pharmacolog’s patent application EP 04 736 476 “Method and device for analysis, verification and quality assurance of drugs for infusion”. “This is a real breakthrough for our business and the market positioning of our DrugLog product. Since the patent claims also cover the integration to Drug Information and treatment planning systems, Pharmacolog has now the potential to take the lead for safe delivery of IV drugs, where the right drug, with the right concentration is given to the right patient at the right time”, says Hans Dahlin, the founder and CEO of Pharmacolog.